Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset
On 12 March 2018, Biogen Inc (BIIB US) announced an agreement to acquire Pfizer Inc (PFE US)'s first-in-class, Phase 2b ready AMPA receptor...
197 Views
Will Actinogen Ace Alzheimer's?
Alzheimer’s disease is an incurable neurodegenerative disorder that robs the affected individuals of memory, self-care and quality of life,...
215 Views
Biosimilar Battlefield: An Update
Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...
418 Views
Insider Trading Alleged as Sanofi Continues Its Shopping Spree
The Securities and Exchange Commission (SEC) believes that insider trading occurred around Sanofi (SAN FP) 's $11.6 billion deal for Bioverativ Inc...
212 Views
Genomics as an Investment Theme
Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...
305 Views